<DOC>
	<DOCNO>NCT02131545</DOCNO>
	<brief_summary>Quetiapine , second generation antipsychotic , available oral tablet . However , topical rectal formulation produce compound pharmacy . There data available suggest topical rectal formulation provide serum level similar oral medication . In clinical setting , oral administration quetiapine possible ( example , patient extremely ill physically mentally ) , clinicians pharmacist collaborate case time administer quetiapine compound dosage formulation rectal topical formulation . Despite clinical effectiveness &amp; quot ; &amp; quot ; formulation , available study investigate blood level drug oral form . The investigator therefore design pharmacokinetic study evaluate systemic absorption quetiapine oral , rectal topical formulation . If investigator able demonstrate detectable level rectal topical quetiapine formulation compare oral form , knowledge enhance clinical psychiatric practice provide broad route administration quetiapine commonly use drug psychiatric symptom .</brief_summary>
	<brief_title>Pharmacokinetic Study Comparing Topical , Rectal , Oral Quetiapine</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Inclusion Criteria Healthy adult volunteer ( 18‐65 year old ) willing undergo general health screen consist blood pressure , heart rate , respiratory rate , height , weight , temperature , electrocardiogram identify . The parameter must meet consider adult healthy volunteer inclusion study : Blood pressure le 160/99 mmHg great 105/50 mmHg Heart rate 50‐100 beat per minute Respiratory rate 10‐30 breath per minute Temperature 34 °C 37.5°F Corrected QT interval &lt; 470 msec Liver function test less 1.5 time upper limit normal Estimated creatinine clearance ( estimate Cockcroft Gault formulation ) great 60 mL/min Female participant complete urine pregnancy test must result negative find Exclusion : 1 . Allergy quetiapine , Lipoderm polyethylene glycol 2 . Currently take quetiapine 3 . Pregnant , plan become pregnant breast feed 4 . Over 30 % ideal body weight 5 . History active cardiovascular disease ( except hypertension meeting inclusion criterion blood pressure ) , severe kidney disease ( i.e . needing dialysis ) , liver disease 6 . History schizophrenia , bipolar disorder , substance use disorder ( exclude nicotine use disorder stable unipolar depression ( See ) ) 7 . Unstable unipolar depression , define hospitalization depression within 1 year change antidepressant regimen within 6 month 8 . History seizure seizure disorder 9 . Parkinson 's disease , Huntington 's disease , tardive dyskinesia diagnose movement disorder 10 . History of/or active hematologic/oncologic illness 11 . Dementia 12 . Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome 13 . History organ transplant 14 . History gastric bypass 15 . Contraindications suppository administration 16 . With Ostomy , chronic diarrhea 17 . Diabetes , type 1 type 2 18 . Prolong correct QT interval ( &gt; 470 msec ) history congenital long QT syndrome 19 . Open wound ( ) unhealed wound ( ) topical medication application site ( anterior forearm ) 20 . Active latent tuberculous currently prescribe pharmacotherapy treatment 21 . Currently prescribe take last 7 day , medication know interaction quetiapine compound risk adverse event associate quetiapine : QTc prolong medication : Antipsychotics Vaughan Williams Class IA , IB , IC , III antiarrhythmic Antiinfective agent ( exclude topical agent , oral penicillin , oral cephalosporin ) Antiemetics Methadone Cisapride Cimetidine Divalproex sodium/valproic acid Tetrabenazine Solifenacin Tricyclic antidepressant Tizanidine Fingolimod Increase quetiapine concentration , previously mention Paroxetine Fluoxetine Fluvoxamine Nondihydropyridine calcium channel blocker ( verapamil , diltiazem ) Tamoxifen Cyclosporin ( exclude ophthalmic formulation ) Nefazodone Decrease quetiapine level , previously mention Bosentan Carbamazepine Glucocorticoids Modafinil Primidone St. John 's wort Barbiturates Phenytoin 22 . Vulnerable population exclude ( i.e . prisoner , ward state , emancipate minor , child , pregnant woman ) 23 . Inability receive telephone call purpose postintervention followup 24 . Inability unwillingness individual give write informed consent 25 . NonEnglish speaking population</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>quetiapine</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>dementia</keyword>
	<keyword>delirium</keyword>
	<keyword>palliative care</keyword>
</DOC>